Blockade of CD47 enhances the elimination of CD47-positive tumor cells across multiple preclinical models and has demonstrated efficacy in early phase clinical trials in different tumor entities, including hematological malignancies and solid tumors, while being well-tolerated (7–19). Here, CD47 is linked to neoplasm.